ClinicalTrials.gg
CompletedNCT07142850Updated Nov 28, 2025

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HRS-9190 in Healthy Adults

A Phase 1 interventional study of HRS-9190 in Skeletal Muscle Relaxation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is divided into two parts. The first part adopts a single-center, randomized, single-blind, placebo-controlled dose escalation trial design to investigate the safety, tolerability, pharmacokinetics (PK), and effects on the QTc interval in healthy subjects after a single administration of HRS-9190 for injection at doses of 3 times or 6 times the ED95.

The second part uses a single-center, open-label trial design to examine the safety, tolerability, PK, pharmacodynamics (PD), and reversal effect of neostigmine (in combination with atropine) after intravenous bolus injection and continuous intravenous infusion of the loading dose (2 times the ED95) of HRS-9190 under different anesthesia regimens.

02

Conditions studied

  • Skeletal Muscle Relaxation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Before the trial, the subjects have been fully informed of the nature, significance, potential benefits, possible inconveniences, and potential risks and discomforts of the trial. They can understand the procedures and methods of this study, are willing to strictly abide by the requirements of the entire clinical study, and voluntarily sign the form.
  2. Aged between 18 and 45 years (inclusive) at the time of signing the informed consent form, with both males and females eligible;
  3. classification of Class I;
  4. At the screening period, male subjects must weigh ≥50 kg, female subjects must weigh ≥45 kg, and the (BMI = weight (kg)/height² (m²)) is between 19 and 28 kg/m² (inclusive);
  5. Female subjects of must agree to use highly effective and avoid donating eggs from the time of signing the informed consent form until 3 months after the last dose of the product. Serum pregnancy tests at the screening and baseline periods must be negative, and they must not be breastfeeding. Male subjects whose partners are females of childbearing potential must agree to use highly effective contraception and avoid donating sperm from the time of signing the informed consent form until 3 months after the last dose of the investigational product.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history or current clinical acute or chronic diseases of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, or metabolic abnormalities, who are deemed unsuitable for enrollment by the investigator;
  2. Subjects with a history of neuromuscular diseases (such as myotonic dystrophy, poliomyelitis, myasthenia gravis, botulism) or a history of poliomyelitis;
  3. Subjects with a history of anesthetic complications (such as a history of malignant hyperthermia or a family history of malignant hyperthermia, or those susceptible to malignant hyperthermia (patients with congenital diseases such as idiopathic scoliosis, strabismus, ptosis, umbilical hernia, inguinal hernia, etc.));
  4. Subjects with a history of asthma, a history of airway diseases requiring treatment or anatomical airway abnormalities, or signs of airway abnormalities assessed during screening airway examination that may affect laryngoscope insertion or tracheal intubation;
  5. During the screening or baseline period: subjects with abnormal physical examination results as judged by the study doctor; subjects with clinically significant abnormal or those with persistently/repeatedly > 450 ms in males and > 470 ms in females; subjects with hyperkalemia or hypokalemia that are judged by the investigator to be abnormal and clinically significant;
  6. Subjects with a known history of allergy to the study drug or its , or those with an allergic constitution (allergic to 2 or more drugs and foods);
  7. Subjects who have undergone major surgery within 6 months before screening, or have a history of surgery that may significantly affect the pharmacokinetic characteristics or safety evaluation of the study drug (such as liver or kidney transplantation), or plan to undergo surgery during the trial;
  8. Subjects with to the following drugs (midazolam, propofol, sufentanil, neostigmine, atropine, and sevoflurane): acute angle-closure glaucoma, allergy to eggs, egg products, soybeans or soybean products, epilepsy, angina pectoris, ventricular tachycardia, mechanical intestinal obstruction, urinary tract obstruction, arrhythmia, sinus bradycardia, hypotension, increased vagal tone, benign prostatic hyperplasia, high fever, moderate/moderate hepatic insufficiency, and the following symptoms related to halogenated anesthetics (liver dysfunction, jaundice, fever, or eosinophilia), etc.;
  9. Subjects who have used any drugs that inhibit or induce hepatic drug metabolism (such as inducers-barbiturates, carbamazepine, phenytoin, , omeprazole; inhibitors-SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines) within 1 month before drug administration;
  10. Subjects who have taken antihistamines or antidepressants within 3 months before screening;
  11. Subjects who have been vaccinated within 1 month before screening or plan to be vaccinated during the trial;
  12. Subjects who have used any drugs or health products (including Chinese herbal medicines) within 7 half-lives or 14 days (whichever is longer) before drug administration, or who are known to may need to receive other drug treatments during the trial period as determined during screening;
  13. Subjects who have participated in a clinical trial and received the trial drug within 3 months before screening, or plan to participate in other clinical trials during the trial period;
  14. Subjects who have donated blood/lost ≥ 400 mL of blood (except for physiological blood loss in women), received blood transfusion or used blood products within 3 months before screening, or plan to donate blood during the trial or within 1 month after the end of the trial;
  15. Subjects who smoked more than 5 cigarettes per day on average within 3 months before screening, or cannot quit smoking during the trial;
  16. Subjects who drank more than 14 units of alcohol per week on average within 3 months before screening (1 unit ≈ 285 mL of beer with 3.5% alcohol content, or 25 mL of spirits with 40% alcohol content, or 85 mL of wine with 12% alcohol content), or who do not agree to abstain from alcohol during the trial;
  17. Subjects who drank excessive tea, coffee, or caffeinated beverages (on average more than 8 cups per day, 1 cup = 200 mL) within 3 months before screening;
  18. Subjects who consumed special foods (such as grapefruit, grapefruit juice or foods/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeine-containing foods or beverages, etc.) within 48 hours before drug administration;
  19. Subjects with positive results in one or more of the tests for surface antigen, virus antibody, syphilis, or antibody;
  20. Subjects with a history of drug abuse or positive drug abuse screening results;
  21. Subjects with positive alcohol breath screening results;
  22. Subjects with difficult venous blood collection/intolerance to venipuncture, or with a history of needle phobia/blood phobia;
  23. Female subjects who are pregnant or breastfeeding;
  24. Subjects who may not be able to complete the study for other reasons or who are deemed unsuitable for inclusion by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Group A: Intravenous injection, 3×ED95

    Drug: HRS-9190

  • Experimental
    Group B: Intravenous injection, 6×ED95

    Drug: HRS-9190

  • Experimental
    Group C: 2×ED95 (intravenous bolus) + intravenous infusion

    Drug: HRS-9190

  • Experimental
    Group D: 2×ED95 (intravenous bolus) + intravenous infusion

    Drug: HRS-9190

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: from ICF signing date to Day 7

  2. Plasma histamine levels

    Time frame: 10 minutes before midazolam administration and 40 minutes after administration

Secondary outcomes

  1. AUC0-t of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  2. AUC0 inf of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  3. Cmax of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  4. Tmax of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  5. t1/2 of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  6. CL of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  7. λz of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  8. VZ of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  9. VSS of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  10. MRTinf of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  11. AUC%Extrap of HRS-9190

    Time frame: 0 hour to 8 hour after administration

  12. The C-QTc relationship of HRS-9190.

    Time frame: At least 90 minutes before the administration of midazolam to 24 hours after the administration of the investigational product

  13. The maximum percentage of T1 suppression

    Time frame: 0 hour to about 1 hour after the end of infusion

  14. Onset time

    Time frame: 0 hour to about 1 hour after the end of infusion

  15. Duration of action

    Time frame: 0 hour to about 1 hour after the end of infusion

  16. Recovery time

    Time frame: 0 hour to about 1 hour after the end of infusion

  17. Recovery index

    Time frame: 0 hour to about 1 hour after the end of infusion

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Oct 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 27, 2025
StartActual
Aug 26, 2025
Primary completionActual
Oct 31, 2025
CompletionActual
Oct 31, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07142850
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 26, 2025
Primary completion
Oct 31, 2025
Completion
Oct 31, 2025
Last update
Nov 28, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9190

Start the discussion